Lycia Therapeutics raises $317.5 million in upsized Nasdaq IPO as Windward Bio eyes listing

Lycia Therapeutics completed an initial public offering on Nasdaq, selling shares that generated roughly $317.5 million after the offering was upsized.

The company’s debut on the exchange marks a significant financing milestone for the biotech, providing capital to advance its pipeline.

At the same time, immunology-focused Windward Bio signaled that it plans to pursue a public listing, hoping to benefit from the same market enthusiasm.

Both moves reflect growing investor interest in specialty biotech firms seeking growth capital.